A Phase 1 interventional study of TU7710 and Normal saline in Hemophilia a, Hemophilia B and Blood Coagulation Disorders, sponsored by TiumBio Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-27.
Sponsored by TiumBio Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Hemophilia A with a site in Korea, Republic of — 8 open to participants now, 16 under way, 12 of them phase 3. Hemophilia A · Korea, Republic of.
Among the 49 studies in Hemophilia A with a site in Korea, Republic of, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2023, is one of 3 in phase 1, and was the 45th registered.
845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
Browse Hemophilia A studies →8 of the 49 studies in Hemophilia A with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Argentina and 15 more countries
Ages 12+
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Argentina and 19 more countries
Ages 12+
Bayer · Sites in Korea, Republic of
Ages 12+
Pfizer · Sites in Korea, Republic of, United States, Australia and 11 more countries
Ages 18+ · Men only
Pfizer · Sites in Korea, Republic of, United States, Argentina and 19 more countries
Ages 1–17 · Men only
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.
This study: 19 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 33
First in 2011; this study’s year is marked. 5 started in 2023.
This study's enrollment of 40 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 134 across the 39 interventional studies, 190 across the 10 observational. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 49 have an industry lead sponsor. The 10 most frequent:
TiumBio Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
TiumBio Co., Ltd. has 1 study filed under Hemophilia A — fewer than ten, so there is no comparison to draw.
3 of the studies in Hemophilia A with a site in Korea, Republic of that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04644575Phase 3Bioverativ, a Sanofi companyLong-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | 2027-01-15 |
| NCT05662319Phase 3SanofiA Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia | 2027-03-25 |
| NCT07416526Phase 3Hoffmann-La RocheA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A | 2027-09-23 |
Add all 3 to your calendar (.ics) → With an account.
Among the 49 studies in Hemophilia A with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1a, double-blind, randomized, placebo- controlled, SAD study to assess safety, tolerability, PK, and PD of TU7710 in warfarin treated healthy male participants.
The 40 subjects will be divided into 5 cohorts, and the subjects assigned to each cohort will be randomly assigned with 6 persons receiving TU7710 and 2 persons receiving a placebo for TU7710. Each cohort will proceed in sequence and the next cohort study will be decided by the Safety Monitoring Committee (SMC) .
Subjects will be participated in the study after warfarin anti-coagulation to maintain the INR between 2.00 and 3.00 as a preventive measure for potential thrombosis prior to the IP administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TU7710 of escalating 5 doses
Drug: TU7710
Placebo of TU7710 at corresponding TU7710 dose level
Drug: Normal saline
In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1\~4 PK, PD, safety, and exploratory efficacy data.
Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
Number and proportion of participants with adverse events
Number and proportion of participants with adverse events/ adverse reaction /SAE overall and by treatment group
Time frame: 30 days post-dose
Number of subjects with significant abnormal laboratory values
Mean with standard deviation, median, maximum, minimum results of laboratory values in each treatment group. The laboratory parameters that will be assessed are clinical chemistry, hematology and urinalysis.
Time frame: 30 days post-dose
ADA and Neutralizing antibody results
Incidence of subjects with ADA and Nab positive results
Time frame: 30 days post-dose
Number of subjects with significant abnormal Electrocardiography (ECG) findings
Mean with standard deviation, median, maximum, minimum results of ECG results in each treatment group. The ECG parameters that will be assessed are heart rate, PR interval, QRS interval, QT interval, and QTcF interval.
Time frame: 30 days post-dose
Number of subjects With Significant Abnormal vital sign findings
Mean with standard deviation, median, maximum, minimum results of vital sign values in each treatment group. The vital signs that will be assessed are body temperature, pulse rate, respiratory rate, and systolic and diastolic blood pressure.
Time frame: 30 days post-dose
Pharmacokinetics assessment_Maximum concentration
Maximum plasma VIIa activity level in each dose level
Time frame: 4 days post-dose
Pharmacokinetics assessment_AUC last
Area under plasma activity-time curve after TU7710 single administration from time zero to last quantifiable concentration
Time frame: 4 days post-dose
Pharmacokinetics assessment_AUC inf
Area Under the Plasma activity-time curve after TU7710 single administration From Time Zero Extrapolated to Infinity
Time frame: 4 days post-dose
Pharmacokinetics assessment_Clearance
Clearance after TU7710 single administration
Time frame: 4 days post-dose
Pharmacokinetics assessment_Volume of distribution
Volume of distribution after TU7710 single administration
Time frame: 4 days post-dose
Pharmacokinetics assessment_Dose proportionality
Regression analysis using the power model between the log-converted Cmax, AUClast, and the log-converted dose can be performed, and each parameter adjusted by dose can be calculated and compared between the dose groups
Time frame: 4 days post-dose
Pharmacokinetics assessment_Tmax
Time from administration to maximum plasma VIIa level in each dose level
Time frame: 4 days post-dose
Pharmacodynamic assessment_INR change from baseline
INR measurement change from baseline to day 5 in each treatment group and dose level
Time frame: 5 days post-dose
Pharmacodynamic assessment_PT change from baseline
PT measurement change from baseline to day 5 in each treatment group and dose level
Time frame: 5 days post-dose
Pharmacodynamic assessment_aPTT change from baseline
aPTT measurement change from baseline to day 5 in each treatment group and dose level
Time frame: 5 days post-dose
Pharmacokinetics assessment_incremental recovery
Incremental recovery after TU7710 single administration expressed as the ratio of measured peak level against dose per bodyweight
Time frame: 4 days post-dose
Ran from Aug 2023 to primary completion in Aug 2024, 12 months.
Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 12 months is above that.
Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TiumBio Co., Ltd.